Standardize transcatheter aortic valve implantation with corevalve self expandable prosthesis and post procedurals management

ranscatheter aoric valve implantaion (TAVI) is a therapeuic alternaive to surgical aoric valve replacement (SAVR) or palliaive medical therapy for paients with symptomaic severe aoric valve stenosis (AVS) 1-5 .The high surgical risk for a paients with aoric valve stenosis has to be assessed jointly with the cardiac surgeon and the cardiac anaesthesiologist, as indicated in the guidelines for valvular heart disease management issued by the European society of cardiology in 2012 6 .Results from registries and trial are favourable with unexpected results of prosthesis performance and survival rate at 3 and 5 years of follow up [7][8][9][10][11][12][13] .TAVI carries higher risk of post procedural adverse events than convenional percutaneous cardiovascular intervenions, due to the baseline clinical condiion of the paients and to the associated comorbidiies.Therefore, careful paient monitoring in a intensive care unit (ICU) during the irst 48 hours seems to be extremely important to early detect and manage complicaions, as well as decrease the rate of adverse events and the length of in-hospital stay.